ArticleMediators of inflammation2014
Rotenone remarkably attenuates oxidative stress, inflammation, and fibrosis in chronic obstructive uropathy.
Article in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Mitochondrial complex I in focus: mechanisms and therapeutic strategies of urinary system diseases.Frontiers in physiology · 2026Review
- Mitochondrial Signaling, the Mechanisms of AKI-to-CKD Transition and Potential Treatment Targets.International journal of molecular sciences · 2024Review
- Renal-Protective Roles of Lipoic Acid in Kidney Disease.Nutrients · 2023Review
- Integrated proteomic and metabolomic profile analyses of cardiac valves revealed molecular mechanisms and targets in calcific aortic valve disease.Frontiers in cardiovascular medicine · 2022Article
- Renoprotective potentials of small molecule natural products targeting mitochondrial dysfunction.Frontiers in pharmacology · 2022Review
- miR‑30a‑5p mitigates autophagy by regulating the Beclin‑1/ATG16 pathway in renal ischemia/reperfusion injury.International journal of molecular medicine · 2021Article
- Pharmacotherapy against Oxidative Stress in Chronic Kidney Disease: Promising Small Molecule Natural Products Targeting Nrf2-HO-1 Signaling.Antioxidants (Basel, Switzerland) · 2021Review
- Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies.International journal of molecular sciences · 2019Review
- Intervention of mitochondrial activity attenuates cisplatin-induced acute kidney injury.International urology and nephrology · 2019Article
- Inhibition of mitochondrial complex I by rotenone protects against acetaminophen-induced liver injury.American journal of translational research · 2019Article
- 5-Aminolevulinic acid regulates the immune response in LPS-stimulated RAW 264.7 macrophages.BMC immunology · 2018Article
- Article
- Article
- MnTBAP therapy attenuates the downregulation of sodium transporters in obstructive kidney disease.Oncotarget · 2018Article
- Impaired Citric Acid Cycle in Nondiabetic Chronic Kidney Disease.EBioMedicine · 2017Article
- Intermedin attenuates renal fibrosis by induction of heme oxygenase-1 in rats with unilateral ureteral obstruction.BMC nephrology · 2017Article
- Overexpressed cyclophilin B suppresses aldosterone-induced proximal tubular cell injury both in vitro and in vivo.Oncotarget · 2016Article
- Resveratrol ameliorates renal injury in spontaneously hypertensive rats by inhibiting renal micro-inflammation.Bioscience reports · 2016Article
- MnTBAP Therapy Attenuates Renal Fibrosis in Mice with 5/6 Nephrectomy.Oxidative medicine and cellular longevity · 2016Article
- Mediators and mechanisms of heat shock protein 70 based cytoprotection in obstructive nephropathy.Cell stress & chaperones · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial abnormality has been shown in many kidney disease models. However, its role in the pathogenesis of chronic kidney diseases (CKDs) is still uncertain. In present study, a mitochondrial complex I inhibitor rotenone was applied to the mice subjected to unilateral ureteral obstruction (UUO). Following 7-days rotenone treatment, a remarkable attenuation of tubular injury was detected by PAS staining. In line with the improvement of kidney morphology, rotenone remarkably blunted fibrotic response as shown by downregulation of fibronectin (FN), plasminogen activator inhibitor-1 (PAI-1), collagen I, collagen III, and α-SMA, paralleled with a substantial decrease of TGF-β 1. Meanwhile, the oxidative stress markers thiobarbituric acid-reactive substances (TBARS) and heme oxygenase 1 (HO-1) and inflammatory markers TNF-α, IL-1β, and ICAM-1 were markedly decreased. More importantly, the reduction of mitochondrial DNA copy number and mitochondrial NADH dehydrogenase subunit 1 (mtND1) expression in obstructed kidneys was moderately but significantly restored by rotenone, suggesting an amelioration of mitochondrial injury. Collectively, mitochondrial complex I inhibitor rotenone protected kidneys against obstructive injury possibly via inhibition of mitochondrial oxidative stress, inflammation, and fibrosis, suggesting an important role of mitochondrial dysfunction in the pathogenesis of obstructive kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.